We are live on ! Find out more
PASG icon

Passage Bio

85 hedge funds and large institutions have $78.4M invested in Passage Bio in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 36 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.07% less ownership

Funds ownership: 3.96%3.88% (-0.07%)

21% less funds holding

Funds holding: 10885 (-23)

41% less capital invested

Capital invested by funds: $133M → $78.4M (-$54.8M)

44% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 36

58% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 33

Holders
85
Holders Change
-23
Holders Change %
-21.3%
% of All Funds
1.43%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
20
Reduced
36
Closed
33
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
-$26K

PASG Hedge Fund Activity: Q2 2022 in Review

85 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2022, worth a combined $78.4M — down 41% from $133M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of PASG and 14 opened new positions — a net loss of 19 holders — while 36 trimmed existing stakes and 20 added.

The largest buyer was OrbiMed, adding an estimated $3.74M. The largest seller was BlackRock, cutting an estimated $4.49M.

  • 85 institutional investors held Passage Bio (PASG) as of Q2 2022, down from 108 in Q1 2022.
  • Funds reported $78.4M of Passage Bio stock for Q2 2022, down 41% quarter-over-quarter.
  • 14 funds opened new Passage Bio positions in Q2 2022 and 33 closed out, a net change of -19 holders.
  • The largest Passage Bio buyer in Q2 2022 was OrbiMed, an estimated $3.74M added.
  • The largest Passage Bio seller in Q2 2022 was BlackRock, an estimated $4.49M sold.

Based on aggregated 13F filings for Q2 2022.